Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Generics
Israel’s Teva Pharmaceutical Industries today reported results for the quarter ended March 31, 2025. 7 May 2025
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
The US Food and Drug Administration (FDA) has approved Incyte’s Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). 16 May 2025
Pharmaceutical
Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial intelligence-powered drug discovery - even as many companies in the sector remain unprofitable. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Biotechnology
US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million. 16 May 2025
Biotechnology
New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. 16 May 2025
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Biotechnology
US pharma giant Merck & Co today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. 15 May 2025
Biotechnology
Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the US Food and Drug Administration (FDA), said the drug’s developer, AbbVie. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Latest In Brief for Teva Pharmaceutical Industries
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Relevant Ones To Watch News
Fibrosis drug developer Tvardi Therapeutics has hit the ground running after completing its merger with troubled US biotech Cara Therapeutics, inheriting a Nasdaq listing and a bolstered cash position. 14 May 2025
28 April 2025
28 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze